Oppenheimer has recently initiated Inari Medical Inc (NARI) stock to Outperform rating, as announced on December 17, 2024, according to Finviz. Earlier, on September 18, 2024, Stifel had initiated the ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Truist has recently initiated Solid Biosciences Inc (SLDB) stock to Buy rating, as announced on Today, according to Finviz. Earlier, on December 13, 2024, Wedbush had initiated the stock to Outperform ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7.Stay Ahead of the ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

Qure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4 ...

Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...